Search

Farzad Haerizadeh

from San Diego, CA
Age ~55
Get Report
Also known as:
Frazad Haerizadeh, Fazad Haerizadeh
Phone and address:
13954 Royal Dornoch Sq, San Diego, CA 92128
Connected to:
Mary E Haerle, 89Peter J Haerle, 89Jean M Haerling, 68Diana M Haerr, 48Duane J Haerr, 57John Haerr, 56Scott E Haerr, 47Steven A Haerr, 69Philip E Haers, 84David J Haertel, 55

Farzad Haerizadeh Phones & Addresses

  • 13954 Royal Dornoch Sq, San Diego, CA 92128
  • Los Altos, CA
  • 1670 El Camino Real, Menlo Park, CA 94025 (650) 328-1793
  • Stanford, CA

Work

Company: F1 oncology Dec 2017 to Nov 2019 Position: Vice president, discovery and preclinical research and platform development

Education

School / High School: Stanford University 2006 to 2008

Skills

Molecular Biology • Microbiology • Cell • Assay Development • Biotechnology • Genomics • Biofuels • Synthetic Biology • Systems Biology • Protein Engineering • Biochemistry • Dna • Proteomics • Life Sciences • Fermentation • Metabolic Engineering • Protein Chemistry • Pcr • Purification • Yeast • Protein Purification • Qpcr • Cell Biology • Protein Expression • High Throughput Screening • Transcriptomics • Lifesciences • Dna Sequencing • Bioinformatics • Genetics • Hplc

Languages

English

Industries

Biotechnology

Resumes

Resumes

Farzad Haerizadeh Photo 1

Vice President, Molecular Platform Development

View page
Location:
13954 Royal Dornoch Sq, San Diego, CA 92128
Industry:
Biotechnology
Work:
F1 Oncology Dec 2017 - Nov 2019
Vice President, Discovery and Preclinical Research and Platform Development
Synthetic Genomics Nov 2015 - Feb 2016
Mammalian Synthetic Biology and Xenotransplantation
Intrexon Corporation Mar 2014 - Nov 2015
Director, Genome Editing and Genome Engineering, Immuno-Oncology
Life Technologies May 2011 - Mar 2014
Synthetic Biology Genome Editing and Cell Engineering Leader
Codexis, Inc. Feb 2010 - May 2011
Staff Scientist Ii, Pathway Engineering, Synthetic Biology
Education:
Stanford University 2006 - 2008
University of Tehran
Masters, Biotechnology, Engineering University of Melbourne
Doctorates, Doctor of Philosophy, Biology
Skills:
Molecular Biology
Microbiology
Cell
Assay Development
Biotechnology
Genomics
Biofuels
Synthetic Biology
Systems Biology
Protein Engineering
Biochemistry
Dna
Proteomics
Life Sciences
Fermentation
Metabolic Engineering
Protein Chemistry
Pcr
Purification
Yeast
Protein Purification
Qpcr
Cell Biology
Protein Expression
High Throughput Screening
Transcriptomics
Lifesciences
Dna Sequencing
Bioinformatics
Genetics
Hplc
Languages:
English

Publications

Us Patents

Molecular Biology Tools For Algal Engineering

View page
US Patent:
20130065313, Mar 14, 2013
Filed:
Aug 13, 2012
Appl. No.:
13/584615
Inventors:
Farzad Haerizadeh - San Diego CA, US
Todd Peterson - Coronado CA, US
Wen Chen - Carslbad CA, US
Ewa Lis - Lakeside CA, US
Assignee:
LIFE TECHNOLOGIES CORPORATION - Carlsbad CA
International Classification:
C12N 15/87
C09K 3/00
C12N 1/12
US Classification:
435471, 4352571, 4352573, 4352576, 25218212
Abstract:
The present invention provides compositions and methods for the genetic manipulation of Algal cells. The compositions and methods allow enhanced transfer of genetic material into Algal cells and the cloning and selection of genetically modified cells. Expression of proteins encoded by the genetic material will be enhanced by the methods and compositions of the invention.

Use Of An Endogenous 2-Micron Yeast Plasmid For Gene Over Expression

View page
US Patent:
20120088271, Apr 12, 2012
Filed:
Sep 29, 2011
Appl. No.:
13/249219
Inventors:
Farzad Haerizadeh - San Diego CA, US
Fernando Valle - Burlingame CA, US
Guillaume Cottarel - Mountain View CA, US
Assignee:
Codexis, Inc. - Redwood City CA
International Classification:
C12P 21/06
C12N 1/19
C12N 15/63
C12N 15/64
US Classification:
435 691, 435 912, 435 914, 4352542, 43525421, 4353201
Abstract:
Methods and compositions for making stable recombinant yeast 2 μm plasmids are provided. Homologous recombination is performed to clone a nucleic acid of interest into the yeast 2 μm plasmid. Heterologous nucleic acid subsequences are recombined between an FLP and a REP2 gene of the plasmid.

Methods And Compositions For The Modification And Delivery Of Lymphocytes

View page
US Patent:
20220340927, Oct 27, 2022
Filed:
Aug 31, 2020
Appl. No.:
17/639281
Inventors:
- West Palm Beach FL, US
James Joseph Onuffer - Alameda CA, US
Farzad Haerizadeh - San Diego CA, US
Frederic Vigant - San Diego CA, US
Anirban Kundu - West-Bay, Grand Cayman, KY
Assignee:
Exuma Biotech Corp. - West Palm Beach FL
International Classification:
C12N 15/86
A61K 35/17
C07K 14/725
Abstract:
The present disclosure provides methods and compositions for genetically modifying lymphocytes, for example T cells and/or NK cells. In some embodiments, the methods include reaction mixtures, and resulting cell formulations, that are created using whole blood, or a component thereof that is not a PBMC, and additionally comprise T cells and recombinant retroviral particles having polynucleotides that encode a CAR. In some embodiments, modified lymphocytes are reintroduced into a subject subcutaneously. In some embodiments, polynucleotides that provide T cells the ability to regulate cell survival and proliferation in response to binding to a CAR, are provided.

Methods And Compositions For Genetically Modifying Lymphocytes To Express Polypeptides Comprising The Intracellular Domain Of Cd79A And Cd79B

View page
US Patent:
20220306698, Sep 29, 2022
Filed:
Apr 12, 2022
Appl. No.:
17/659007
Inventors:
- West Palm Beach FL, US
Ghiabe H. Guibinga - San Diego CA, US
Farzad Haerizadeh - San Diego CA, US
Frederic Vigant - West Palm Beach FL, US
Anirban Kundu - , US
Assignee:
Exuma Biotech Corp. - West Palm Beach FL
International Classification:
C07K 14/005
C12N 15/86
C07K 14/705
C07K 16/28
C07K 14/725
C07K 14/54
A61K 47/69
A61K 35/17
C12N 7/00
Abstract:
The present disclosure provides methods and compositions for genetically modifying lymphocytes, for example T cells and/or NK cells, in shorter times than previously and/or in whole blood or a component thereof. In some embodiments a lymphodepletion filter assembly is used before or after forming a reaction mixture where lymphocytes are contacted with recombinant retroviral particles in a closed system, to genetically modify the lymphocytes.

Methods And Compositions For Transducing Lymphocytes And Regulating The Activity Thereof

View page
US Patent:
20210403952, Dec 30, 2021
Filed:
Sep 6, 2021
Appl. No.:
17/467425
Inventors:
- West Palm Beach FL, US
James Joseph ONUFFER - Alameda CA, US
Ghiabe H. GUIBINGA - San Diego CA, US
Farzad HAERIZADEH - San Diego CA, US
Anirban KUNDU - West-Bay, KY
Assignee:
EXUMA BIOTECH CORP. - West Palm Beach FL
International Classification:
C12N 15/86
C12N 15/113
C07K 14/725
C07K 14/705
C07K 16/30
A61K 39/00
C07K 16/28
C12N 5/0783
C07K 14/715
C07K 14/005
C07K 14/54
C12N 15/10
C07K 16/32
Abstract:
The present disclosure provides methods for genetically modifying lymphocytes and methods for performing adoptive cellular therapy that include transducing T cells and/or NK cells. The methods can include inhibitory RNA molecule(s) and/or engineered signaling polypeptides that can include a lymphoproliferative element, and/or a chimeric antigen receptor (CAR), for example a microenvironment restricted biologic CAR (MRB-CAR). Additional elements of such engineered signaling polypeptides are provided herein, such as those that drive proliferation and regulatory elements therefor, as well as replication incompetent recombinant retroviral particles and packaging cell lines and methods of making the same. Numerous elements and methods for regulating transduced and/or genetically modified T cells and/or NK cells are provided, such as, for example, those including riboswitches, MRB-CARs, recognition domains, and/or pH-modulating agents.

Methods And Compositions For Genetically Modifying Lymphocytes In Blood Or In Enriched Pbmcs

View page
US Patent:
20210317408, Oct 14, 2021
Filed:
Sep 2, 2019
Appl. No.:
17/272631
Inventors:
- West Palm Beach FL, US
James Joseph Onuffer - Alameda CA, US
Farzad Haerizadeh - San Diego CA, US
Frederic Vigant - West-Bay, Grand Cayman, KY
Anirban Kundu - West-Bay, Grand Cayman, KY
Assignee:
Exuma Biotech Corp. - West Palm Beach FL
International Classification:
C12N 5/0783
C07K 16/28
C07K 14/47
C12N 15/11
C07K 14/725
C12N 7/00
Abstract:
The present disclosure provides methods and compositions for genetically modifying lymphocytes, for example T cells and/or NK cells, in shorter times than previously and/or in whole blood or a component thereof. In some embodiments a lymphodepletion filter assembly is used before or after forming a reaction mixture where lymphocytes are contacted with recombinant retroviral particles in a closed system, to genetically modify the lymphocytes.

Methods And Compositions For Genetically Modifying Lymphocytes To Express Polypeptides Comprising The Intracellular Domain Of Mpl

View page
US Patent:
20210107949, Apr 15, 2021
Filed:
Dec 2, 2020
Appl. No.:
17/110028
Inventors:
- West Palm Beach FL, US
James Joseph Onuffer - Alameda CA, US
Ghiabe H. Guibinga - San Diego CA, US
Farzad Haerizadeh - San Diego CA, US
Frederic Vigant - Villers-Sous-Saint-Leu, FR
Anirban Kundu - West Bay, KY
Assignee:
Exuma Biotech Corp. - West Palm Beach FL
International Classification:
C07K 14/005
C12N 7/00
C12N 15/86
C07K 14/705
C07K 16/28
C07K 14/725
C07K 14/54
A61K 47/69
A61K 35/17
Abstract:
The present disclosure provides methods and compositions for genetically modifying lymphocytes, for example T cells and/or NK cells, in shorter times than previously and/or in whole blood or a component thereof. In some embodiments a lymphodepletion filter assembly is used before or after forming a reaction mixture where lymphocytes are contacted with recombinant retroviral particles in a closed system, to genetically modify the lymphocytes.

Methods And Compositions For Transducing Lymphocytes And Regulating The Activity Thereof

View page
US Patent:
20170356010, Dec 14, 2017
Filed:
Jul 8, 2017
Appl. No.:
15/644778
Inventors:
- West Palm Beach FL, US
James Joseph Onuffer - Alameda CA, US
Ghiabe H. Guibinga - San Diego CA, US
Farzad Haerizadeh - San Diego CA, US
International Classification:
C12N 15/86
C07K 14/705
C07K 16/30
A61K 39/00
C12N 15/113
C07K 14/725
Abstract:
The present disclosure provides methods for genetically modifying lymphocytes and methods for performing adoptive cellular therapy that include transducing T cells and/or NK cells. The methods can include inhibitory RNA molecule(s) and/or engineered signaling polypeptides that can include a lymphoproliferative element, and/or a chimeric antigen receptor (CAR), for example a microenvironment restricted biologic CAR (MRB-CAR). Additional elements of such engineered signaling polypeptides are provided herein, such as those that drive proliferation and regulatory elements therefor, as well as replication incompetent recombinant retroviral particles and packaging cell lines and methods of making the same. Numerous elements and methods for regulating transduced and/or genetically modified T cells and/or NK cells are provided, such as, for example, those including riboswitches, MRB-CARs, recognition domains, and/or pH-modulating agents.
Control profile
Farzad Haerizadeh from San Diego, CA, age ~55 Get Report